Patent ID: 7381407
Filing Date: 2008-06-03
Classification: A61K,C07K,C12N,G01N

Abstract:
1. A method of detecting the presence of prostate-specific membrane antigen (PSMA) expressed by prostate cancer cells, comprising contacting a sample of cells in vivo with a first labeled monoclonal antibody having an antigen-binding region binding to an epitope in the extracellular domain of PSMA, and detecting any antibody-bound PSMA on the membrane of the prostate cancer cells, in which the antigen-binding region of the first labeled antibody is capable of competitively inhibiting the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by hybridoma 3F5.4G6 having ATCC accession number HB 12060, 3D7-1.1 having ATCC accession number HB 12309, 4E10-1.14 having ATCC accession number HB 12310, 3C9 having ATCC accession number HB 12484, 2C7 having ATCC accession number HB 12490, 1G3 having ATCC accession number HB 12489, 4C8B9 having ATCC accession number HB 12492; 1G9 having ATCC accession number HB 12495, 3C6 having accession number HB 12491, or 4D4 having accession number HB 12493, thereby detecting the presence of prostate-specific membrane antigen (PSMA) expressed by prostate cancer cells.